Sabadell Asset Management, S.A S.G.I.I.C Gilead Sciences, Inc. Transaction History

Sabadell Asset Management, S.A S.G.I.I.C

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jan 23, 2024	SELL	$77.31 - $88.08 $4.92 Million - $5.61 Million	-63,689 Closed	0 $0
Q3 2022 Jan 23, 2024	SELL	$59.54 - $68.01 $675,183 - $771,233	-11,340 Reduced 15.11%	63,689 $4.17 Billion
Q1 2022 Jan 23, 2024	SELL	$57.92 - $72.58 $1.97 Million - $2.47 Million	-34,081 Reduced 31.24%	75,029 $4.58 Billion
Q4 2021 Jan 23, 2024	BUY	$64.88 - $73.64 $109,841 - $124,672	1,693 Added 1.58%	109,110 $7.84 Billion
Q3 2021 Jan 23, 2024	BUY	$67.69 - $73.03 $2.15 Million - $2.32 Million	31,787 Added 42.03%	107,417 $7.5 Billion
Q2 2021 Jan 23, 2024	BUY	$63.47 - $69.35 $4.8 Million - $5.24 Million	75,630 New	75,630 $5.21 Billion

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Sabadell Asset Management, S.A S.G.I.I.C, based on Form 13F filings with the SEC.

Stay updated on Sabadell Asset Management, S.A S.G.I.I.C with notifications on news.